New data are reported from an ongoing, prospective, nonrandomized phase 1/2 study of eltrombopag added to immunosuppressive therapy for patients with treatment-naive severe aplastic anemia.
A team of investigators conducted a cross-sectional analysis to assess the effect of a geriatric assessment tool on older patients with hematologic malignancies.
A team of investigators sought to evaluate outcomes following combination treatment with eprenetapopt and azacitadine in TP53-mutant myelodysplastic syndromes, as well as in oligoblastic acute myeloid leukemia.
A team of investigators conducted a systematic literature review and meta-analysis to determine the effectiveness of combined calcium channel blocker and chelation therapy for reducing iron overload in patients with thalassemia.
Investigators noted the importance of improving educational efforts about the safety and efficacy of matched sibling donor HSCT for children with sickle cell disease.
Among pediatric patients with relapsed or refractory acute lymphoblastic leukemia, the use of blinatumomab may provide encouraging response rates.
For patients with sickle cell disease, HSCT may not be associated with a significant increase in CKD incidence or prevalence following transplantation.
Investigators compared clinical outcomes between unfit patients with newly diagnosed AML who were treated with either azacitidine or decitabine.
For younger patients with relapsed or refractory AML, the use of decitabine with venetoclax may be an appropriate salvage therapy, and is comparable to intensive chemotherapy regimens.
Detection of driver mutations acquired very early in life and life-long clonal expansion may predict clinical outcomes and interventions for patients with myeloproliferative neoplasms.
